Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab

摘要: Abstract Background Patients with metastatic colorectal cancer (mCRC) activating mutations at codon 12 or 13 of the KRAS gene are currently excluded from treatment monoclonal antibodies against epidermal growth factor receptor (EGFR), for example, cetuximab. Occasionally, some these patients benefit cetuximab, especially a mutation 13. We conducted an analysis to study influence p.G13D in mCRC who were treated Materials and Methods analyzed status 110 cetuximab between September 2003 October 2008 Hospital Clinico, San Carlos. compared progression-free survival, overall response rate according status. Results those other showed no statistically significant differences survival (4.96 months [95% CI, 3.04-6.89 months] vs. 3.10 1.58-4.61 months]; hazard ratio [HR] 0.88 44-1.75]; P = .72) (8.2 4.2-12.1 14.6 8.0-21.2 HR 0.50 0.23-1.09]; .084). wild-type tumors have longer (7.30 4.48-10.12 0.46 0.23-0.91]; .025) (19.0 10.2-27.8 0.32 0.15-0.69]; .004) than p.G13D-mutated tumors. Differences not observed groups. Conclusion do appear These results support current clinical practice.